A Phase 3 interventional study of Febuxostat and Febuxostat in Gout, sponsored by Takeda. Completed. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2012-02-02.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.
Among the 29 studies testing febuxostat in Gout, this one is the 5th largest by enrollment, is the only one that started in 2002, is one of 10 in phase 3, and was the 1st registered.
347 studies on the registry are indexed under Gout; 49 are open to participants now.
Browse Gout studies →1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:
Haiphong University of Medicine and Pharmacy
Healthy volunteers
Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 760 is above the median of 83 across 286 interventional studies indexed under Gout.
Median enrollment 109 across the 29 interventional studies. Of the 27 that completed or were terminated, 18 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 29 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Gout by Takeda: none open now, none under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 15 studies in Gout by Takeda, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2002, is one of 6 in phase 3, and was the 1st registered.
Takeda’s Gout studies by the year they started, since 2001.
1 of the studies testing febuxostat in Gout that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07369622Haiphong University of Medicine and PharmacyHLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness | 2027-06-20 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies testing febuxostat in Gout, from their registry updates:
Among Takeda’s 15 in Gout:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of febuxostat, once daily (QD), versus allopurinol in subjects with gout.
This was a randomized, controlled, double-blind study of 52 weeks duration. Subjects receiving prior urate-lowering therapy underwent a 2-week washout period prior to randomization. Subjects were then randomized to one of three treatment groups: febuxostat 80 milligram (mg), febuxostat 120 mg, or allopurinol 300 mg. Naproxen (250 mg twice daily) or colchicine (0.6 mg once daily) was provided for prophylaxis of acute gout flares during the washout period and the first 8 weeks of double-blind treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Febuxostat
Drug: Febuxostat
Drug: Allopurinol
Febuxostat 80 mg, orally, once daily for up to 52 weeks.
Also known as: TMX-67, Tei-6720, Uloric
Febuxostat 120 mg, orally, once daily for up to 52 weeks.
Also known as: TMX-67, Tei-6720, Uloric
Allopurinol 300 mg, capsules, orally, once daily for up to 52 weeks.
Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL)
Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject.
Time frame: Last 3 Visits (up to 52 weeks)
Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 28 Visit
Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Week 28 visit was summarized.
Time frame: Week 28
Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 52 Visit
Serum urate values were obtained at the Week 52 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Week 52 visit was summarized.
Time frame: Week 52
Percentage of Subjects With Serum Urate <6.0 mg/dL at Final Visit
The percentage of subjects whose serum urate was \<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject.
Time frame: Final Visit (up to 52 weeks)
Percent Change From Baseline in Serum Urate Levels at Week 28.
Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as \[(week 28 - baseline levels/baseline)\]\*100 and summarized.
Time frame: Baseline and Week 28
Percent Change From Baseline in Serum Urate Levels at Week 52.
Serum urate values were obtained at the Week 52 visit. The percent change in serum urate was calculated as \[(week 52 - baseline levels/baseline)\]\*100 and summarized.
Time frame: Baseline and Week 52
Percent Change From Baseline in Serum Urate Levels at Final Visit
The percent change in serum urate from baseline to the Final visit was calculated as \[(Final Visit - baseline levels/baseline)\]\*100 and summarized. The Final visit was the last visit with a serum urate value. The timing of the final visit may have differed for each subject.
Time frame: Baseline and Final Visit (up to 52 weeks)
Percent Change From Baseline in Tophus Size at Week 28, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as \[(Week 28 - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero.
Time frame: Baseline and Week 28
Percent Change From Baseline in Tophus Size at Week 52, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as \[(Week 52 - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 52 visit, the size was assumed to be zero.
Time frame: Baseline and Week 52
Percent Change From Baseline in Tophus Size at Final Visit, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.
Percent change in primary tophus size was calculated as \[(Final Visit - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject.
Time frame: Baseline and Final Visit (up to 52 weeks)
Change From Baseline in Total Number of Tophi at Week 28 in Subjects With Palpable Tophi at Screening.
The change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 28 visit, the total count was assumed to be zero.
Time frame: Baseline and Week 28
Change From Baseline in Total Number of Tophi at Week 52 in Subjects With Palpable Tophi at Screening.
The change from baseline at Week 52 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 52 visit, the total count was assumed to be zero.
Time frame: Baseline and Week 52
Change From Baseline in Total Number of Tophi at Final Visit in Subjects With Palpable Tophi at Screening.
Change in number of tophi/subject calculated for the subset of subjects with palpable tophi at Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject.
Time frame: Baseline and Final Visit (up to 52 weeks)
Percentage of Subjects Requiring Treatment for Gout Flares Between Weeks 8 and 52.
The percentage of subjects requiring treatment for a gout flare between Weeks 8 and 52 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once.
Time frame: Weeks 8 through 52
Subjects were enrolled at 112 investigative sites, 106 in the United States and 6 in Canada, from 11 July 2002 to 20 February 2004.
| Milestone | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Started | 256 | 251 | 253 |
| Completed | 168 | 153 | 187 |
| Not completed | 88 | 98 | 66 |
| Withdrew: Lost to follow-up | 25 | 18 | 21 |
| Withdrew: Adverse event | 16 | 23 | 8 |
| Withdrew: Gout flare | 10 | 28 | 9 |
| Withdrew: Personal reason(s) | 19 | 13 | 13 |
| Withdrew: Other | 11 | 14 | 14 |
| Withdrew: Protocol violation | 7 | 2 | 1 |
Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject.
| Percentage of subjects | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL) | 53 | 62 | 21 |
Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Week 28 visit was summarized.
| Percentage of subjects | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 28 Visit | 72 | 82 | 42 |
Serum urate values were obtained at the Week 52 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Week 52 visit was summarized.
| Percentage of subjects | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 52 Visit | 81 | 82 | 39 |
The percentage of subjects whose serum urate was \<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject.
| Percentage of subjects | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Percentage of Subjects With Serum Urate <6.0 mg/dL at Final Visit | 74 | 80 | 36 |
Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as \[(week 28 - baseline levels/baseline)\]\*100 and summarized.
| percent change from baseline | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Percent Change From Baseline in Serum Urate Levels at Week 28. | -46.3 ± 15.76 | -53.5 ± 18.20 | -34.8 ± 12.92 |
Serum urate values were obtained at the Week 52 visit. The percent change in serum urate was calculated as \[(week 52 - baseline levels/baseline)\]\*100 and summarized.
| percent change from baseline | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Percent Change From Baseline in Serum Urate Levels at Week 52. | -47.7 ± 17.50 | -53.0 ± 19.31 | -34.8 ± 13.56 |
The percent change in serum urate from baseline to the Final visit was calculated as \[(Final Visit - baseline levels/baseline)\]\*100 and summarized. The Final visit was the last visit with a serum urate value. The timing of the final visit may have differed for each subject.
| percent change from baseline | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Percent Change From Baseline in Serum Urate Levels at Final Visit | -44.7 ± 19.10 | -51.5 ± 19.91 | -33.0 ± 15.33 |
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as \[(Week 28 - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero.
| percent change from baseline | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Percent Change From Baseline in Tophus Size at Week 28, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening. | -29.5 (-66.0 to 4.1) | -49.5 (-80.0 to -34.9) | -28.6 (-54.9 to 0.0) |
The percent change from baseline in primary tophus size as determined by physical measurement was calculated as \[(Week 52 - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 52 visit, the size was assumed to be zero.
| percent change from baseline | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Percent Change From Baseline in Tophus Size at Week 52, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening. | -83.4 (-100 to -15.6) | -65.5 (-85.5 to -38.9) | -49.7 (-96.0 to 0.0) |
Percent change in primary tophus size was calculated as \[(Final Visit - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject.
| percent change from baseline | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Percent Change From Baseline in Tophus Size at Final Visit, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening. | -51.7 (-100 to -8.3) | -43.8 (-83.0 to 0.0) | -39.6 (-65.0 to 1.5) |
The change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 28 visit, the total count was assumed to be zero.
| number of tophi | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Change From Baseline in Total Number of Tophi at Week 28 in Subjects With Palpable Tophi at Screening. | 0.0 (0.0 to 0.0) | 0.0 (-1.0 to 0.0) | 0.0 (0.0 to 0.0) |
The change from baseline at Week 52 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 52 visit, the total count was assumed to be zero.
| number of tophi | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Change From Baseline in Total Number of Tophi at Week 52 in Subjects With Palpable Tophi at Screening. | 0.0 (-1.0 to 0.0) | -1.0 (-1.0 to 0.0) | 0.0 (-1.0 to 0.0) |
Change in number of tophi/subject calculated for the subset of subjects with palpable tophi at Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject.
| number of tophi | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Change From Baseline in Total Number of Tophi at Final Visit in Subjects With Palpable Tophi at Screening. | 0.0 (-1.0 to 0.0) | 0.0 (-1.0 to 0.0) | 0.0 (-1.0 to 0.0) |
The percentage of subjects requiring treatment for a gout flare between Weeks 8 and 52 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once.
| percentage of subjects | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Percentage of Subjects Requiring Treatment for Gout Flares Between Weeks 8 and 52. | 64 | 70 | 64 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Febuxostat 80 mg QD | — | 10/256 (3.9%) | 164/256 (64.1%) |
| Febuxostat 120 mg QD | — | 19/251 (7.6%) | 145/251 (57.8%) |
| Allopurinol 300 mg QD | — | 18/253 (7.1%) | 167/253 (66%) |
| Event | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Coronary Artery Disorders NECCardiac disorders | 0/256 | 0/251 | 4/253 |
| Heart Failures NECCardiac disorders | 3/256 | 1/251 | 0/253 |
| Ischaemic Coronary Artery Disorders NECCardiac disorders | 3/256 | 2/251 | 2/253 |
| Ventricular Arrhythmias and Cardiac ArrestCardiac disorders | 0/256 | 2/251 | 1/253 |
| Abdominal and Gastrointestinal InfectionsInfections and infestations | 0/256 | 1/251 | 2/253 |
| Renal Failure and ImpairmentRenal and urinary disorders | 2/256 | 0/251 | 0/253 |
| Supraventricular ArrhythmiasCardiac disorders | 1/256 | 1/251 | 0/253 |
| Acute and Chronic PancreatitisGastrointestinal disorders | 0/256 | 1/251 | 0/253 |
| Intestinal HaemorrhagesGastrointestinal disorders | 0/256 | 1/251 | 0/253 |
| Intestinal Ulcers and Perforation NECGastrointestinal disorders | 0/256 | 1/251 | 0/253 |
| Event | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD |
|---|---|---|---|
| Upper Respiratory Tract InfectionsInfections and infestations | 77/256 | 53/251 | 72/253 |
| Joint Related Signs and SymptomsMusculoskeletal and connective tissue disorders | 39/256 | 32/251 | 37/253 |
| Musculoskeletal and Connective Tissue Signs and Symptoms NECMusculoskeletal and connective tissue disorders | 35/256 | 38/251 | 37/253 |
| Diarrhoea (Excl Infective)Gastrointestinal disorders | 27/256 | 25/251 | 16/253 |
| Headache NECNervous system disorders | 23/256 | 23/251 | 22/253 |
| Nausea and Vomiting SymptomsGastrointestinal disorders | 19/256 | 13/251 | 8/253 |
| Oedema NECGeneral disorders | 18/256 | 8/251 | 8/253 |
| Upper Respiratory Tract Signs and SymptomsRespiratory, thoracic and mediastinal disorders | 13/256 | 10/251 | 17/253 |
| Neurological Signs and Symptoms NECNervous system disorders | 17/256 | 9/251 | 7/253 |
| Liver Function AnalysesInvestigations | 13/256 | 16/251 | 12/253 |
| Age, Customized(subjects) | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD | Total |
|---|---|---|---|---|
| <45 years | 75 | 71 | 84 | 230 |
| 45 years to <65 years | 140 | 133 | 125 | 398 |
| ≥65 years | 41 | 47 | 44 | 132 |
| Age Continuous(years) | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD | Total |
|---|---|---|---|---|
| Mean | 51.8 ± 11.69 | 52.0 ± 12.12 | 51.6 ± 12.63 | 51.8 ± 12.13 |
| Sex: Female, Male(Participants) | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD | Total |
|---|---|---|---|---|
| Female | 13 | 8 | 10 | 31 |
| Male | 243 | 243 | 243 | 729 |
| Body Mass Index(subjects) | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD | Total |
|---|---|---|---|---|
| <18.5 kilogram per meter² (kg/m²) | 0 | 0 | 0 | 0 |
| 18.5 kg/m² to <25 kg/m² | 15 | 12 | 7 | 34 |
| 25 kg/m² to <30 kg/m² | 75 | 87 | 89 | 251 |
| ≥30 kg/m² | 166 | 152 | 154 | 472 |
| missing | 0 | 0 | 3 | 3 |
| Calculated Creatinine Clearance(subjects) | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD | Total |
|---|---|---|---|---|
| <50 milliliters per minute (mL/min) | 13 | 8 | 13 | 34 |
| 50 mL/min to <80 mL/min | 77 | 90 | 68 | 235 |
| 80 mL/min to <120 mL/min | 138 | 130 | 140 | 408 |
| ≥120 mL/min | 28 | 23 | 29 | 80 |
| missing | 0 | 0 | 3 | 3 |
| Presence of Primary Palpable Tophus(subjects) | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD | Total |
|---|---|---|---|---|
| Yes | 52 | 53 | 46 | 151 |
| No, but other tophi present | 1 | 2 | 3 | 6 |
| No and no other tophi present | 203 | 196 | 204 | 603 |
| Race/Ethnicity(subjects) | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol 300 mg QD | Total |
|---|---|---|---|---|
| White | 193 | 199 | 195 | 587 |
| Black or African American | 24 | 20 | 18 | 62 |
| Hispanic | 22 | 17 | 19 | 58 |
| Asian | 10 | 9 | 6 | 25 |
| Other | 7 | 6 | 15 | 28 |
No study locations are listed for this record.
The record gives a start of Jul 2002, a primary completion of Feb 2004 and a completion of Feb 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 5 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Febuxostat